• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Definitive Healthcare Announces CEO Transition

    1/16/24 4:05:00 PM ET
    $DH
    Computer Software: Prepackaged Software
    Technology
    Get the next $DH alert in real time by email

    Jason Krantz, Founder and Executive Chairman, to Serve as Interim CEO

    Company Reaffirms Fourth Quarter 2023 Guidance and Issues Preliminary Guidance for 2024

    FRAMINGHAM, Mass., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare (Nasdaq: DH) (the "Company"), an industry leader in healthcare commercial intelligence, today announced that Robert Musslewhite has stepped down as Chief Executive Officer and as a member of the Board of Directors to transition to a new phase of leadership for the Company. Jason Krantz, Founder and Executive Chairman of Definitive Healthcare, has been appointed interim Chief Executive Officer. The Board has engaged a leading global executive search firm to commence a process to identify a permanent CEO.

    "Over the last several months, Definitive Healthcare has taken decisive, strategic steps designed to better position our organization to capture opportunities, deliver world-class products to our customers and create value for our shareholders over the long term," said Mr. Krantz. "We believe these changes – combined with our proprietary data, powerful tools and deep subject matter expertise – provide us with a solid foundation to drive further growth. While we look for the next leader to propel Definitive Healthcare's next chapter, I am excited to work even more closely with our talented team to ensure we continue to drive excellence and performance in this transitional period."

    Mr. Krantz founded Definitive Healthcare in 2011. He served as CEO of the Company for more than a decade, scaling the business into a leading data-as-a-service provider to the U.S. healthcare industry. Under his leadership, Definitive Healthcare expanded to over 2,500 customers, reached over $200 million in annual revenue and executed an IPO in September 2021. In August 2022, Mr. Krantz transitioned to the role of Executive Chairman and since then has continued to play an active role in the Company.

    Mr. Krantz continued, "We sincerely thank Robert for his contributions to Definitive Healthcare and for laying the foundation for the next phase of growth for the business. The Board remains focused on Definitive Healthcare reaching its full potential and will work to ensure this transition is smooth while we undertake the search process."

    Mr. Musslewhite commented, "It has been a been a privilege to lead a company as exceptional as Definitive Healthcare. I look forward to closely following the future success of Definitive Healthcare and wish Jason, the Board and the entire team all the best."

    Prior to founding Definitive Healthcare, Mr. Krantz founded and served as CEO of Infinata, a SaaS based provider of intelligence to the pharmaceutical industry under the brand BioPharm Insight. In addition, he has co-founded and helped build several intelligence and analytics companies, including Energy Acuity, a privately held provider of intelligence on the alternative energy market, and Xtelligent Media, a privately held integrated marketing company focused on the healthcare industry. Mr. Krantz holds a B.S. in Finance and Computer Science from Boston College and an M.B.A. from Harvard Business School.

    Financial Update

    In addition to announcing the leadership transition, the Company is reaffirming its financial guidance for Q4 2023, as provided on November 3, 2023, and is issuing preliminary guidance for 2024:

    • Full year 2024 Revenue is expected to grow 5-7% compared to full year 2023 guidance; and
    • Full year 2024 Adjusted EBITDA margin is expected to increase approximately 200 basis points compared to full year 2023 guidance.

    The Company will release its fourth quarter and full year 2023 financial results on Wednesday, February 28, 2024 after market close.

    A reconciliation Adjusted EBITDA to net loss is not available on a forward-looking basis without unreasonable effort due to the uncertainty regarding, and the potential variability of, expenses that may be incurred in the future. For example, stock-based compensation expense-related charges are impacted by the timing of employee stock transactions, the future fair market value of our common stock, and our future hiring and retention needs, all of which are difficult to predict and subject to constant change. Accordingly, a reconciliation is not available without unreasonable effort and the Company is unable to assess the probable significance of the unavailable information, although it is important to note that these factors could be material to its results computed in accordance with GAAP.

    About Definitive Healthcare

    At Definitive Healthcare, our passion is to transform data, analytics, and expertise into healthcare commercial intelligence. We help clients uncover the right markets, opportunities, and people, so they can shape tomorrow's healthcare industry. Our SaaS platform creates new paths to commercial success in the healthcare market, so companies can identify where to go next. Learn more at definitivehc.com.

    Forward-Looking Statements

    This press release includes forward-looking statements that reflect our current views with respect to future events and financial performance. Such statements are provided under the "safe harbor" protection of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that do not relate solely to historical or current facts, and can generally be identified by words or phrases written in the future tense and/or preceded by words such as "likely," "will," "should," "may," "anticipates," "intends," "plans," "seeks," "believes," "estimates," "expects" or similar words or variations thereof, or the negative thereof, references to future periods, or by the inclusion of forecasts or projections, but these terms are not the exclusive means of identifying such statements. Examples of forward-looking statements include, but are not limited to, statements we make regarding our outlook, financial guidance, the executive transition, our business, growth strategies, and statements reflecting our expectations about our ability to execute on our strategic plans, achieve future growth and achieve our financial goals.    

    Forward-looking statements in this press release are based on our current expectations and assumptions regarding our business, the economy and other future conditions. Because forward-looking statements relate to the future, by their nature, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. As a result, our actual results may differ materially from those contemplated by the forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include the following: our inability to realize expected business or financial benefits from acquisitions and the risk that our acquisitions or investments could prove difficult to integrate, disrupt our business, dilute stockholder value and adversely affect our business, financial condition and results of operations; our inability to achieve the anticipated cost savings, operating efficiencies or other benefits of our internal restructuring activities; the war between Russia and Ukraine, the evolving conflict in Israel and surrounding areas, global geopolitical tension and worsening macroeconomic conditions; actual or potential changes in international, national, regional and local economic, business and financial conditions, including recessions, inflation, rising interest rates, volatility in the capital markets and related market uncertainty; the impact of worsening macroeconomic conditions on our new and existing customers; our inability to acquire new customers and generate additional revenue from existing customers; our inability to generate sales of subscriptions to our platform or any decline in demand for our platform and the data we offer; the competitiveness of the market in which we operate and our ability to compete effectively; the failure to maintain and improve our platform, or develop new modules or insights for healthcare commercial intelligence; the inability to obtain and maintain accurate, comprehensive or reliable data, which could result in reduced demand for our platform; the risk that our recent growth rates may not be indicative of our future growth; the inability to achieve or sustain GAAP or non-GAAP profitability in the future compared to historical levels as we increase investments in our business; the loss of our access to our data providers; the failure to respond to advances in healthcare commercial intelligence; an inability to attract new customers and expand subscriptions of current customers; the risk of cyber-attacks and security vulnerabilities; litigation, investigations or other legal, governmental or regulatory actions; the possibility that our security measures are breached or unauthorized access to data is otherwise obtained; the risk that additional material weaknesses or significant deficiencies that will occur in the future; and the risks of being required to collecting sales or other related taxes for subscriptions to our platform in jurisdictions where we have not historically done so.  

    Additional factors or events that could cause our actual performance to differ from these forward-looking statements may emerge from time to time, and it is not possible for us to predict all of them. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, our actual financial condition, results of operations, future performance and business may vary in material respects from the performance projected in these forward-looking statements. 

    For additional discussion of factors that could impact our operational and financial results, refer to our Quarterly Report on Form 10-Q for the three months ended September 30, 2023, as well as our Current Reports on Form 8-K and other subsequent SEC filings, which are or will be available on the Investor Relations page of our website at ir.definitivehc.com and on the SEC website at www.sec.gov. 

    All information in this press release speaks only as of the date on which it is made. We undertake no obligation to publicly update this information, whether as a result of new information, future developments or otherwise, except as may be required by law. 

    Contacts

    Investors:

    Brian Denyeau

    ICR for Definitive Healthcare

    [email protected]

    (646) 277-1251

    Media:

    Justin Steinman

    [email protected]



    Primary Logo

    Get the next $DH alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $DH

    DatePrice TargetRatingAnalyst
    5/9/2025Buy → Neutral
    BTIG Research
    1/13/2025$4.00Equal Weight → Underweight
    Barclays
    12/20/2024$5.00Equal-Weight
    Stephens
    9/17/2024$7.00Buy
    BTIG Research
    7/31/2024$7.00 → $5.00Neutral → Underweight
    JP Morgan
    5/8/2024$11.50 → $9.00Overweight → Equal-Weight
    Morgan Stanley
    1/17/2024Buy → Hold
    Needham
    1/5/2024Buy → Hold
    Canaccord Genuity
    More analyst ratings

    $DH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Definitive Healthcare Announces Timing of Its Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast

    FRAMINGHAM, Mass., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare") (NASDAQ:DH), an industry leader in healthcare market data and analytics, today announced that it will report financial results for its fourth quarter and full year ended December 31, 2025, on Thursday, February 26, 2026 after market close. The company will host a conference call and webcast at 5:00 PM (ET) / 2:00 PM (PT) to discuss the company's financial results. A live audio webcast of the event will be available on the Definitive Healthcare's Investor Relations website at https://ir.definitivehc.com/. A live dial-in will be available at 877-358-7298 (domestic) or +1-848-488-9244

    1/29/26 4:05:00 PM ET
    $DH
    Computer Software: Prepackaged Software
    Technology

    Definitive Healthcare to Present at the 28th Annual Needham Growth Conference

    FRAMINGHAM, Mass., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Definitive Healthcare (NASDAQ:DH), an industry leader in healthcare market data and analytics, today announced that its Chief Financial Officer, Casey Heller, will present at the 28th Annual Needham Growth Conference. The Definitive Healthcare presentation is scheduled for Wednesday, January 14, 2026, at 9:30 a.m. Eastern Time. A live webcast of the presentation will be available on the Events page of the Definitive Healthcare investor relations website at https://ir.definitivehc.com/. A replay of the webcast will also be available for a limited time. About Definitive HealthcareDefinitive Healthcare is a data and analytics company focu

    1/7/26 4:05:00 PM ET
    $DH
    Computer Software: Prepackaged Software
    Technology

    Definitive Healthcare Reports Financial Results for Third Quarter Fiscal Year 2025

    FRAMINGHAM, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare" or the "Company") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter ended September 30, 2025.  Third Quarter 2025 Financial Highlights: Revenue was $60.0 million, a decrease of 4% from $62.7 million in Q3 2024. Net Loss was $(17.8) million, or (30)% of revenue, compared to $(187.8) million in Q3 2024, inclusive of goodwill impairment charges of $228.2 million, or (300)% of revenue.Adjusted Net Income was $9.7 million, compared to $15.4 million in Q3 2024.Adjusted EBITDA was $18.9 million, or 32% of revenue, compar

    11/6/25 4:05:00 PM ET
    $DH
    Computer Software: Prepackaged Software
    Technology

    $DH
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Definitive Healthcare Corp.

    SCHEDULE 13G/A - Definitive Healthcare Corp. (0001861795) (Subject)

    2/9/26 4:10:50 PM ET
    $DH
    Computer Software: Prepackaged Software
    Technology

    SEC Form 10-Q filed by Definitive Healthcare Corp.

    10-Q - Definitive Healthcare Corp. (0001861795) (Filer)

    11/6/25 4:27:07 PM ET
    $DH
    Computer Software: Prepackaged Software
    Technology

    Definitive Healthcare Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Definitive Healthcare Corp. (0001861795) (Filer)

    11/6/25 4:14:12 PM ET
    $DH
    Computer Software: Prepackaged Software
    Technology

    $DH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EXECUTIVE CHAIRMAN Krantz Jason Ronald covered exercise/tax liability with 44,545 shares, decreasing direct ownership by 4% to 1,016,039 units (SEC Form 4)

    4 - Definitive Healthcare Corp. (0001861795) (Issuer)

    2/3/26 4:12:02 PM ET
    $DH
    Computer Software: Prepackaged Software
    Technology

    Chief Financial Officer Heller Casey covered exercise/tax liability with 1,469 shares, decreasing direct ownership by 0.12% to 1,274,021 units (SEC Form 4)

    4 - Definitive Healthcare Corp. (0001861795) (Issuer)

    2/3/26 4:05:03 PM ET
    $DH
    Computer Software: Prepackaged Software
    Technology

    Chief Financial Officer Heller Casey was granted 195,313 shares, increasing direct ownership by 18% to 1,275,490 units (SEC Form 4)

    4 - Definitive Healthcare Corp. (0001861795) (Issuer)

    1/7/26 4:05:02 PM ET
    $DH
    Computer Software: Prepackaged Software
    Technology

    $DH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Definitive Healthcare downgraded by BTIG Research

    BTIG Research downgraded Definitive Healthcare from Buy to Neutral

    5/9/25 8:41:31 AM ET
    $DH
    Computer Software: Prepackaged Software
    Technology

    Definitive Healthcare downgraded by Barclays with a new price target

    Barclays downgraded Definitive Healthcare from Equal Weight to Underweight and set a new price target of $4.00

    1/13/25 7:41:23 AM ET
    $DH
    Computer Software: Prepackaged Software
    Technology

    Stephens initiated coverage on Definitive Healthcare with a new price target

    Stephens initiated coverage of Definitive Healthcare with a rating of Equal-Weight and set a new price target of $5.00

    12/20/24 7:31:03 AM ET
    $DH
    Computer Software: Prepackaged Software
    Technology

    $DH
    Leadership Updates

    Live Leadership Updates

    View All

    Definitive Healthcare Appoints Kevin Coop as CEO for Next Phase of Company's Growth

    FRAMINGHAM, Mass., May 28, 2024 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced that its Board of Directors has appointed Kevin Coop as the Company's next Chief Executive Officer and as a member of the Board of Directors, each effective June 24, 2024. Mr. Coop succeeds Jason Krantz, founder and Executive Chairman, who has been serving as Interim CEO since January 2024. Mr. Krantz will continue to serve on the Board of Directors as Executive Chairman after the CEO transition. "Kevin is an outstanding leader. He has deep, hands-on experience with data-focused businesses and has a

    5/28/24 8:00:00 AM ET
    $DH
    Computer Software: Prepackaged Software
    Technology

    Established Executive and Milwaukee Business Leader Jim Emling Joins VBA as Executive Chair of the Board of Directors

    Jim Emling, the CEO of Datassential and former long-time president of Milwaukee-based Zywave, has been appointed Executive Chair of the Board of Directors at VBA, the company announced today. "We are delighted to welcome Jim officially to VBA as the Executive Chair," said Michael Clayton, the company's President and CEO. "Jim and I have worked closely together over the last 3 months and his decades of experience scaling high growth software companies combined with his strong ties to the Milwaukee technology sector will be tremendous assets to VBA as we enter our next phase of growth." Emling has deep roots in the Milwaukee technology community. He was the founding CTO of Zywave and serv

    11/28/23 5:00:00 PM ET
    $DH
    $GDRX
    Computer Software: Prepackaged Software
    Technology
    EDP Services

    Definitive Healthcare Names Carrie Lazorchak as Chief Revenue Officer

    FRAMINGHAM, Mass., Oct. 05, 2023 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced that Carrie Lazorchak has been named Chief Revenue Officer, effective November 1, 2023. "I am thrilled to welcome Carrie Lazorchak to Definitive Healthcare as our new Chief Revenue Officer," said Robert Musslewhite, Chief Executive Officer of Definitive Healthcare. "Carrie is a fantastic fit for Definitive Healthcare. Her values and her deep belief in the power of humble collaboration make her a perfect match for our culture. Carrie brings a wealth of experience selling Software as a Service to both enterprise accounts and

    10/5/23 4:05:00 PM ET
    $DH
    Computer Software: Prepackaged Software
    Technology

    $DH
    Financials

    Live finance-specific insights

    View All

    Definitive Healthcare Announces Timing of Its Fourth Quarter and Full Year 2025 Financial Results Conference Call and Webcast

    FRAMINGHAM, Mass., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare") (NASDAQ:DH), an industry leader in healthcare market data and analytics, today announced that it will report financial results for its fourth quarter and full year ended December 31, 2025, on Thursday, February 26, 2026 after market close. The company will host a conference call and webcast at 5:00 PM (ET) / 2:00 PM (PT) to discuss the company's financial results. A live audio webcast of the event will be available on the Definitive Healthcare's Investor Relations website at https://ir.definitivehc.com/. A live dial-in will be available at 877-358-7298 (domestic) or +1-848-488-9244

    1/29/26 4:05:00 PM ET
    $DH
    Computer Software: Prepackaged Software
    Technology

    Definitive Healthcare Reports Financial Results for Third Quarter Fiscal Year 2025

    FRAMINGHAM, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare" or the "Company") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced financial results for the quarter ended September 30, 2025.  Third Quarter 2025 Financial Highlights: Revenue was $60.0 million, a decrease of 4% from $62.7 million in Q3 2024. Net Loss was $(17.8) million, or (30)% of revenue, compared to $(187.8) million in Q3 2024, inclusive of goodwill impairment charges of $228.2 million, or (300)% of revenue.Adjusted Net Income was $9.7 million, compared to $15.4 million in Q3 2024.Adjusted EBITDA was $18.9 million, or 32% of revenue, compar

    11/6/25 4:05:00 PM ET
    $DH
    Computer Software: Prepackaged Software
    Technology

    Definitive Healthcare Announces Timing of Its Third Quarter 2025 Financial Results Conference Call and Webcast

    FRAMINGHAM, Mass., Oct. 23, 2025 (GLOBE NEWSWIRE) -- Definitive Healthcare Corp. ("Definitive Healthcare") (NASDAQ:DH), an industry leader in healthcare commercial intelligence, today announced that it will report financial results for its third quarter ended September 30, 2025, on Thursday, November 6, 2025 after market close. The company will host a conference call and webcast at 5:00 PM (ET) / 2:00 PM (PT) to discuss the company's financial results. A live audio webcast of the event will be available on the Definitive Healthcare's Investor Relations website at https://ir.definitivehc.com/. A live dial-in will be available at 877-358-7298 (domestic) or +1-848-488-9244 (international).

    10/23/25 4:05:00 PM ET
    $DH
    Computer Software: Prepackaged Software
    Technology

    $DH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Definitive Healthcare Corp.

    SC 13G - Definitive Healthcare Corp. (0001861795) (Subject)

    11/12/24 11:54:03 AM ET
    $DH
    Computer Software: Prepackaged Software
    Technology

    SEC Form SC 13G filed by Definitive Healthcare Corp.

    SC 13G - Definitive Healthcare Corp. (0001861795) (Subject)

    10/3/24 9:08:57 PM ET
    $DH
    Computer Software: Prepackaged Software
    Technology

    SEC Form SC 13G/A filed by Definitive Healthcare Corp. (Amendment)

    SC 13G/A - Definitive Healthcare Corp. (0001861795) (Subject)

    2/14/24 4:00:33 PM ET
    $DH
    Computer Software: Prepackaged Software
    Technology